IMMUTEP LTD/S (NASDAQ:IMMP) shares fell 2% during mid-day trading on Friday . The stock traded as low as $1.44 and last traded at $1.44, 322 shares traded hands during mid-day trading. A decline of 99% from the average session volume of 28,484 shares. The stock had previously closed at $1.47.

Several brokerages have issued reports on IMMP. Maxim Group set a $4.00 price objective on IMMUTEP LTD/S and gave the company a “buy” rating in a research report on Wednesday, July 31st. ValuEngine upgraded IMMUTEP LTD/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The company has a market cap of $55.67 million, a P/E ratio of -3.79 and a beta of 1.45. The business has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $1.92.

An institutional investor recently raised its position in IMMUTEP LTD/S stock. Deutsche Bank AG lifted its position in shares of IMMUTEP LTD/S (NASDAQ:IMMP) by 23.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,040 shares of the biotechnology company’s stock after acquiring an additional 18,800 shares during the quarter. Deutsche Bank AG owned approximately 0.37% of IMMUTEP LTD/S worth $184,000 at the end of the most recent reporting period. Institutional investors own 2.10% of the company’s stock.


Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells.

Featured Story: CD Ladder

Receive News & Ratings for IMMUTEP LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMUTEP LTD/S and related companies with's FREE daily email newsletter.